Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity
Optimi Health has established Optimi Australia Pty Ltd, a wholly owned subsidiary handling sales, distribution, and prescriber relationships in Australia, its first commercial market. The subsidiary will sell 5mg psilocybin and 40mg/60mg MDMA capsules to clinics and pharmacies under Australia's Authorised Prescriber Scheme, with products manufactured at the company's Health Canada-licensed GMP facility in Princeton, British Columbia.
Key figures
- Products
- ["5mg psilocybin capsules","40mg MDMA capsules","60mg MDMA capsules"]
- Market note
- Australia is Optimi's first commercial market
- Regulatory scheme
- Australia Authorised Prescriber Scheme
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.